Hormone Therapy for Lung Cancer Nanuet NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Phelps Memorial Hospital Cntr
914-366-3000
701 North Broadway
Sleepy Hollow, NY
Bronx Psychiatric Center
718-931-0600
1500 Waters Place
Bronx, NY
Valley Hospital
201-447-8000
223 North Van Dien Avenue
Ridgewood, NJ
Nyack Hospital
845-348-2000
160 North Midland Avenue
Nyack, NY
Chilton Memorial Hospital
973-831-5000
97 West Parkway
Pompton Plains, NJ
Renaissance Gardens at Cedar Crest
(973) 831-3755
4 Cedar Crest Dr
Pompton Plains, NJ
Montefiore Medical Center
718-920-4321
111 East 210th Street
Bronx, NY
Harlem Hospital Center
212-939-1000
506 Lenox Avenue
New York, NY
Hackensack Univ Medical Center
201-996-2000
30 Prospect Avenue
Hackensack, NJ
Rockland Children'S Psych Ctr
845-359-7400
599 Convent Road
Orangeburg, NY
Data Provided by:
    

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Delayed Prostate Cancer Therapy Nanuet NY
The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues.
- Hormone Therapy Nanuet NY
- Hormone Therapy for Prostate Cancer Nanuet NY
- Hormone Therapy for Early Prostate Cancer Nanuet NY
- Menopausal Hormone Therapy Nanuet NY
- Head and Neck Cancer Treatment Nanuet NY
- Hormone Therapy for Breast Cancer Nanuet NY
- Drug Combo Proves Powerful Against Lung Cancer Nanuet NY
- Breast Cancer Treatment Nanuet NY